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http://dx.doi.org/10.1016/j.chembiol.2012.11.001Picture this: a cyclical molecule that is
stable enough to reach the cell but is small
and inert enough to pass through the cell
membrane and still have active functional
groups, be orally available, and not trigger
the immune system. Macrocycles are
peptides, and the body reacts to them
as a small molecule.
Constructed of rings of 12 atoms or
more, macrocyclic compounds occupy
the middle ground between small mole-
cules at a molecular weight below
500 Da and larger biologics starting at
2000 Da. These plus-sized denizens of
the drug world lurk outside of Lipinski’s
guidelines for drugability, but they com-
prise the majority of biological products‘‘There has been a drive in nature to solve biological problems
with macrocycles.’’ — Nick Terrett, Ph.D.as well as many natural products; for
example, the antibiotics cyclosporine
and erythromycin.
‘‘There has been a drive in nature to
solve biological problems with macro-
cycles,’’ says Nick Terrett, Ph.D, chief
scientific officer at Cambridge, Massa-
chusetts, based Ensemble Therapeutics
(http://www.ensembletx.com). However,
natural product macrocycles were histor-
ically considered too difficult to synthe-
size. Now buoyed by millions of dollars
of pharma collaborations, a dozen or
so biotech companies and academic
research groups are exploring how to
turn synthetic macrocycles into drugs.
Being a bit zaftig in molecular terms
may be advantageous: according to Ter-
rett, many protein targets that comprise
the majority of disease mechanisms and
drug discovery targets require bigger
molecules to bind with high affinity. It
turns out that macrocyclic compounds
can handle the complex protein-protein
interactions that elude small molecules.
Their ring structure can span largely1356 Chemistry & Biology 19, November 21,featureless expanses of protein surface
where small molecules can’t gain traction
and their functional groups can bind to
‘‘hot spots’’ distributed across the active
sites.
While linear peptides or open chain
molecules can hit highly specific cellular
targets, they are likely to be metabolized
before achieving their objective. Macro-
cycles are less likely to be rapidly metab-
olized and cleared before reaching their
target. ‘‘Because these compounds have
a ring structure, they get through cell
membranes more readily than an open
chain structure,’’ says Terrett. According
to Terrett, macrocycles are able to hide
their polar functional groups, which wouldotherwise restrict their passive perme-
ability through a lipidmembrane. Because
the conformations of macrocycles are
already constrained, they can bind more
strongly to cell surfaces than uncon-
strained large molecules, because they
lose less entropy during binding.
‘‘In terms of pharmaceutical properties,
metabolic stability is much higher, the cell
membrane permeability much higher, and
[as] a third feature, because you constrain
the structure, when these compounds
bind to the cell surface, the entropic loss
is reduced,’’ says Terrett.
Macrocycles comprise only a small
subset of molecules, but they are rela-
tively free of patent encumbrances.
‘‘There is a tremendous amount of interest
in this space right now,’’ says Andrei
Yudin, professor of chemistry at the
University of Toronto and founder of
startup Encycle Therapeutics (http://
www.encycletherapeutics.com). ‘‘The low-
hanging fruit is gone. There are more
complex targets, and more complicated
solutions. There is a lot of know-how2012 ª2012 Elsevier Ltd All rights reservedthat is being developed right now.’’
According to Yudin, most of the players
in this space are young and preclinical:
‘‘What the field is looking for is a win.’’
Only two companies so far have
synthetic macrocycles in clinical trials.
Swiss company Polyphor’s (http://www.
polyphor.com) lead compound, POL6326,
a conformationally constrained peptide
antagonist of chemokine receptor 4
(CXCR4), is in phase 2 trials to mobilize
stem cells for transplantation in multiple
myeloma. Polyphor is collaborating with
Boehringer Ingelheim to develop synthetic
macrocyclic molecules of 400–2000 Da
frommodular subunits that can be assem-
bled to display a combination of functional
groups.
Furthest along is Durham, California,
based Tranzyme Pharmaceuticals (http://
www.tranzyme.com), which focuses on
gastrointestinal motility disorders. Tran-
zyme recently completed a phase 2a,
28 day trial in 98 patients of TZP 102,
a ghrelin receptor agonist, to treat symp-
toms of diabetic gastroparesis. A chronic
upper gastrointestinal motility disorder in
which food doesn’t properly empty from
the stomach, gastroparesis affects up to
4%of Americans. Often caused by neuro-
pathic damage resulting from diabetes,
gastroparesis can make mealtime a
misery, causing symptoms including early
satiety, bloating, nausea, vomiting, and
pain. ‘‘It is life altering,’’ says Vipin Garg,
Ph.D., president and chief executive
officer of Tranzyme.
TZP 102 fills an unmet need, according
to Garg, as two of the three drugs for dia-
betic gastroparesis were withdrawn by
the FDA because they caused severe
heart problems. Metoclopramide, the
only drug currently on the market, has
a black box warning. The antibiotic eryth-
romycin is of limited use.
TZP102significantly improvedpatients’
gastroparesis symptoms so far, accord-
ing to Tranzyme. The drug is selective
to the ghrelin receptors located in the
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upper intestinal tract, an accumulation
of nerve cell endings directed by the
autonomous nervous system. ‘‘TZP
102 is a very safe drug,’’ says Helmut
Thomas, Ph.D, senior vice president of
research and preclinical development
at Tranzyme. ‘‘In preclinical studies,
we are not seeing any relevant histo-
pathological changes or alterations in
blood parameters whatsoever, and in
the clinic, we are not seeing adverse
events beyond placebo. The drug has
truly an excellent tolerability profile.’’
Tranzyme has launched a 12 week
randomized, double-blind, phase 2b
study of TZP-102 compared to placebo
in 200 diabetic patients. The stakes are
high, as the company’s former lead
compound, ulimorelin, an intravenous
ghrelin agonist meant to restore normal
bowel function after surgery, recently
failed phase 3 clinical trials. Tranzyme is
also developing TZP-201, a motilin antag-
onist, for chemotherapy-induced diar-
rhea, and TZP-301, a ghrelin antagonist
for treatment of metabolic syndrome and
obesity. In addition, Tranzyme is exploring
macrocycles for antivirals and anti-
infectives.
Tranzyme used its Macrocyclic Tem-
plate Chemistry (MATCH) technology to
produce a screening library of about
40,000 drug-like macrocyclic com-
pounds. The company’s macrocycles
are formed by tethering the ends of small
peptides to make a circular molecule.
Tethers can consist of an aliphatic chain,
an aliphatic-aromatic moiety, or a sugar
molecule. The end result is a peptide lasso
with a molecular weight between 450 and
700 Da. According to Thomas, macro-
cycles behave and are regulated like clas-
sical small molecules. They don’t show
any antigenicity or other immunoactive
characteristics. They are stable for at least
3 years as a drug substance and in formu-
lations such as pills or capsules.
According to Thomas, Tranzyme so far
has used MATCH to inhibit, activate, or
allosterically modulate G protein-coupled
receptor, ion channel, and protein-protein
interaction targets important in oncology
and hyperlipidemia. ‘‘Macrocycles can
be manufactured through convergent
synthesis at very good yields and excep-
tional purity,’’ says Thomas. ‘‘By designthese compounds have an ionizable
amino group as a salt-forming entity,
and the resulting salts crystallize as very
pure compounds.’’ According to Thomas,
Tranzyme’s macrocycles can achieve
very good oral bioavailability, systemic
exposure, plasma half-life, and pharma-
cokinetic profiles in human as well as
animal models.
Since December 2009, Tranzyme has
been engaged in a drug discovery collab-
oration with Bristol-Myers Squibb on
various targets using MATCH. As of
October 2012, the public company had
$125 million in market capitalization, with
$40.8 million in cash at the end of
September 2012.
Assembling Ensemblins
Ensemble Therapeutics takes a different
strategy, focusing on manufacturing vast
macrocycle libraries. The company so
far has synthesized a library of 5.4 million
macrocycle structural variants, dubbed
Ensemblins, with a range of functional-
ities, empirically screens them against
pharma targets, and then fine-tunes the
hits for qualities like oral bioavailability,
affinity, and delivery.
Nick Terrett is also a photographer and
spends his vacations on the lookout for
promising subjects. Terrett formerly led
the chemistry team on cGMP PDE inhibi-
tors at Pfizer for angina and erectile
dysfunction that hunted for potential
applications for a promising vasodilating
compound that ultimately became Viagra.
When he was recruited at Ensemble,
Terrett was intrigued by the potential of
the DNA-programmed chemistry manu-
facturing based on techniques developed
in David Liu’s lab at Harvard. He thought
focusing on macrocycles would be
a good application for the technology.
Ensemble has developed a preclinical
series of small molecule antagonists of
Interleukin-17, a proinflammatory cyto-
kine implicated in multiple inflammatory
and autoimmune diseases. So far, En-
semble has proven that its macrocyclic
molecules are orally anti-inflammatory in
animal models.
Ensemble, founded in 2004, is a private
company with financing from venture
firms including Flagship Ventures, CMEA
Ventures, and Harris & Harris. The
company has collaborations with Genen-Chemistry & Biology 19, November 21, 2012 ªtech, Bristol-Myers Squibb, and Pfizer to
screen its macrocycles against targets
offered by the companies and delivers
optimized leads to partners as well as
nurtures its own in-house drug discovery
program. In November 2012, Ensemble
signed a collaboration agreement with
Boehringer Ingelheim worth up to $186
million in upfront and milestone payments
as well as additional royalties.
Finding the Middle Ground
Newcomer Encycle Therapeutics was
founded last January with $1 million in
seed funding. The company is developing
cradle-shaped macrocyclic peptides,
dubbed nacellins, meant to penetrate
cells. Encycle makes its nacellins using
proprietary amphoteric cyclization re-
agents. Though the technology can be
used to cyclize peptides or nonpeptidic
molecules, Yudin said he plans to focus
on smaller ring structures of 9–18 atoms.
Aside from being a chemist, Yudin is
also an artist, and draws whenever he
can.
According to Yudin, one of the biggest
challenges is to find the ideal molecular
size, producing medium-sized molecules
just above the 500 Da, the size of small
molecules that will be cell permeable,
bioavailable, and have a conformational
space rivaling that of a larger molecule.
‘‘One of the key ways to address this chal-
lenge is to make molecules that are as
much as possible drug-like,’’ says Yudin.
‘‘But medium-sized macrocycles are
difficult to make biologically, thus it is
important to identify synthetic methods
to produce them.’’ According to Yudin,
although companies have innovative
platforms geared toward diversity, the
tendency is to produce big, very specific
molecules that will have very high affinity
to their targets; the risk is they won’t be
at all drug-like. Potentially, they could
stimulate the immune system, may not
be absorbed in the digestive tract, or
won’t penetrate cells. ‘‘So that is really
where the problem is,’’ says Yudin. ‘‘We
are trying to hit the middle spot.’’
It takes a good eye to spot the possibil-
ities; the artistry is synthesizing them into
existence.
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